Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells

Biochemical and Biophysical Research Communications

Volumn 363, Issue 3, 2007, Pages 738-744

  Fuke, Hiroyuki ^a   Shiraki, Katsuya ^a   Sugimoto, Kazushi ^a   Tanaka, Junichiro ^a   Beppu, Tetsuya ^a   Yoneda, Kentaro ^a   Yamamoto, Norihiko ^a   Ito, Keiichi ^a   Masuya, Masahiro ^b   Takei, Yoshiyuki ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY HOSPITAL   (Japan)

Author keywords

Hepatocellular carcinoma; Janus kinase inhibitor; S phase cell cycle arrest; STAT3; TRAIL induced apoptosis

Indexed keywords

CASPASE INHIBITOR; CHECKPOINT KINASE 2; CYCLIN A; CYCLIN D1; CYCLIN E; JANUS KINASE INHIBITOR; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PROTEIN P21; PROTEIN P27; STAT3 PROTEIN; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; PRIORITY JOURNAL; UPREGULATION;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; JANUS KINASES; LIVER NEOPLASMS; PHOSPHORYLATION; S PHASE; STAT3 TRANSCRIPTION FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TYRPHOSTINS;

EID: 34848906227     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.09.049     Document Type: Article

References (36)

1. Okano H., Shiraki K., Inoue H., Kawakita T., Yamanaka T., Deguchi M., et al. Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab. Invest. 83 (2003) 1033-1043
2. Masaki T., Shiratori Y., Rengifo W., Igarashi K., Matsumoto K., Nishioka M., et al. Hepatocellular carcinoma cell cycle: study of Long-Evans cinnamon rats. Hepatology 32 (2000) 711-720
3. Masaki T., Shiratori Y., Rengifo W., Igarashi K., Yamagata M., Kurokohchi K., et al. Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology 37 (2003) 534-543
4. Matsuda Y., and Ichida T. p16 and p27 are functionally correlated during the progress of hepatocarcinogenesis. Med. Mol. Morphol. 39 (2006) 169-175
5. Matsuda Y., Ichida T., Genda T., Yamagiwa S., Aoyagi Y., and Asakura H. Loss of p16 contributes to p27 sequestration by cyclin D(1)-cyclin-dependent kinase 4 complexes and poor prognosis in hepatocellular carcinoma. Clin. Cancer Res. 9 (2003) 3389-3396
6. Klampfer L. Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Curr. Cancer Drug Targets 6 (2006) 107-121
7. Haura E.B., Turkson J., and Jove R. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat. Clin. Pract. Oncol. 2 (2005) 315-324
8. Jing N., and Tweardy D.J. Targeting Stat3 in cancer therapy. Anticancer Drugs 16 (2005) 601-607
9. Yu C.L., Meyer D.J., Campbell G.S., Larner A.C., Carter-Su C., Schwartz J., et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269 (1995) 81-83
10. Bromberg J.F. Activation of STAT proteins and growth control. Bioessays 23 (2001) 161-169
11. Lin Q., Lai R., Chirieac L.R., Li C., Thomazy V.A., Grammatikakis I., et al. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am. J. Pathol. 167 (2005) 969-980
12. Kanda N., Seno H., Konda Y., Marusawa H., Kanai M., Nakajima T., et al. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 23 (2004) 4921-4929
13. Alas S., and Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin. Cancer Res. 9 (2003) 316-326
14. Tomita M., Kawakami H., Uchihara J.N., Okudaira T., Masuda M., Matsuda T., et al. Inhibition of constitutively active Jak-Stat pathway suppresses cell growth of human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. Retrovirology 3 (2006) 22
15. Buettner R., Mora L.B., and Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 8 (2002) 945-954
16. Niu G., Wright K.L., Huang M., Song L., Haura E., Turkson J., et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21 (2002) 2000-2008
17. Epling-Burnette P.K., Liu J.H., Catlett-Falcone R., Turkson J., Oshiro M., Kothapalli R., et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest. 107 (2001) 351-362
18. Sciaccaluga M., Gianfranceschi G.L., Rocco S., Germano G., Roti G., Gorello P., et al. Constitutive phosphorylation of Janus kinase 2 in the GL15 glioblastoma derived human cell line. Oncol. Rep. 17 (2007) 17-23
19. Calvisi D.F., Ladu S., Gorden A., Farina M., Conner E.A., Lee J.S., et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130 (2006) 1117-1128
20. Li W.C., Ye S.L., Sun R.X., Liu Y.K., Tang Z.Y., Kim Y., et al. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clin. Cancer Res. 12 (2006) 7140-7148
21. Yagita H., Takeda K., Hayakawa Y., Smyth M.J., and Okumura K. TRAIL and its receptors as targets for cancer therapy. Cancer Sci. 95 (2004) 777-783
22. Van Geelen C.M., de Vries E.G., and de Jong S. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist. Updat. 7 (2004) 345-358
23. Shin E.C., Seong Y.R., Kim C.H., Kim H., Ahn Y.S., Kim K., et al. Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin. Exp. Mol. Med. 34 (2002) 114-122
24. Yamanaka T., Shiraki K., Sugimoto K., Ito T., Fujikawa K., Ito M., et al. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 32 (2000) 482-490
25. Benekli M., Xia Z., Donohue K.A., Ford L.A., Pixley L.A., Baer M.R., et al. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 99 (2002) 252-257
26. Mora L.B., Buettner R., Seigne J., Diaz J., Ahmad N., Garcia R., et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 62 (2002) 6659-6666
27. Laezza C., Pisanti S., Crescenzi E., and Bifulco M. Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells. FEBS Lett. 580 (2006) 6076-6082
28. Yeo E.J., Ryu J.H., Chun Y.S., Cho Y.S., Jang I.J., Cho H., et al. YC-1 induces S cell cycle arrest and apoptosis by activating checkpoint kinases. Cancer Res. 66 (2006) 6345-6352
29. Lin S.Y., Lai W.W., Chou C.C., Kuo H.M., Li T.M., Chung J.G., et al. Sodium ascorbate inhibits growth via the induction of cell cycle arrest and apoptosis in human malignant melanoma A375 S2 cells. Melanoma Res. 16 (2006) 509-519
30. Ory B., Blanchard F., Battaglia S., Gouin F., Redini F., and Heymann D. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol. Pharmacol. 7 (2007) 333-343
31. Savell J., Ma Y., Morrow K.S., Jove R., Olashaw N., Moseley P.L., et al. AG490 inhibits G1-S traverse in BALB/c-3T3 cells following either mitogenic stimulation or exogenous expression of E2F-1. Mol. Cancer Ther. 3 (2004) 205-213
32. Isomoto H., Kobayashi S., Werneburg N.W., Bronk S.F., Guicciardi M.E., Frank D.A., et al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 42 (2005) 1329-1338
33. Schulze-Bergkamen H., Fleischer B., Schuchmann M., Weber A., Weinmann A., Krammer P.H., et al. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction. BMC Cancer 6 (2006) 232 Oct 2
34. Shiraki K., Sugimoto K., Yamanaka Y., Yamaguchi Y., Saitou Y., Ito K., et al. Overexpression of X-linked inhibitor of apoptosis in human hepatocellular carcinoma. Int. J. Mol. Med. 12 (2003) 705-708
35. Ito T., Shiraki K., Sugimoto K., Yamanaka T., Fujikawa K., Ito M., et al. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 31 (2000) 1080-1085
36. Yamaguchi Y., Shiraki K., Fuke H., Inoue T., Miyashita K., Yamanaka Y., et al. Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death. Oncol. Rep. 14 (2005) 1311-1316